Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 ...

Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6 ...

Leading diversified professional services and investment management company, Colliers (NASDAQ, TSX: CIGI), announced today that the U.S. division of its ...

Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (?21.6 PPriova ...

Cutaneous sarcoidosis occurs in between 20% and 35% of systemic sarcoidosis patients and there is no approved therapy.

Generac Holdings (NYSE:GNRC) has surged 56.65% year-to-date, with shares climbing 36.35% over the past month and 20.51% in the last week. Incredibly, that means Generac is now outperforming 99% of all ...

Arizona turns 114 on Saturday, with free museum open houses, special exhibits and state park events across Southern Arizona celebrating Statehood Day.

Vancouver, British Columbia - Newsfile Corp. - February 9, 2026 - Intrepid Metals Corp. (TSXV: INTR) (OTCQB: IMTCF) ( ...

Q4 2025 earnings call recap: revenue, EPS, margins, cash flow and Q1 2026 outlook, plus Medical and Semi-Cap momentum—read now.

In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1Results favored Vanrafia across multiple ...

Roivant Sciences ROIV stock surged on Friday on positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (CS), an ...

Bristow is the intended launch customer for Electra’s EL9, which is designed for takeoffs and landings with just 150 feet of ...